Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients
Background Global longitudinal strain (GLS) is recommended to detect subclinical changes preceding reduced left ventricular ejection fraction (LVEF) in trastuzumab related cardiotoxicity. Since the possibility to detect signs of acute myocardial deterioration at treatment initiation is not clarified...
Gespeichert in:
| Veröffentlicht in: | Echocardiography (Mount Kisco, N.Y.) N.Y.), 2021-10, Vol.38 (10), p.1702-1710 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Background
Global longitudinal strain (GLS) is recommended to detect subclinical changes preceding reduced left ventricular ejection fraction (LVEF) in trastuzumab related cardiotoxicity. Since the possibility to detect signs of acute myocardial deterioration at treatment initiation is not clarified, the objective of this study was to assess changes in GLS and biomarkers within the first 2 weeks of trastuzumab treatment.
Methods
In a prospective cohort study, 45 patients with non‐metastatic breast cancer (age 54, LVEF 62.8%, GLS ‐19.9%, 40% hypertension) scheduled for trastuzumab treatment were included. Echocardiography and measurement of troponin and NT‐proBrain‐Natriuretic‐Peptide were conducted before initiation of trastuzumab, at days 3, 7, and 14 and after 3, 6, and 9 months.
Results
A significant deterioration in LVEF from 62.8% (SD±3.6) to 58.4% (SD±4.1) (p |
|---|---|
| ISSN: | 0742-2822 1540-8175 |
| DOI: | 10.1111/echo.15190 |